Theranos' Woes May Reshape Private D&O Coverage
An investor's suit accusing Theranos Inc. of misrepresenting its blood-testing technologies and a U.S. Securities and Exchange Commission probe of the startup may lead insurers to broaden exclusions in directors and...To view the full article, register now.
Already a subscriber? Click here to view full article